About crispr therapeutics ag - CRSP
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
CRSP At a Glance
CRISPR Therapeutics AG
Baarerstrasse 14
Zug, Zug 6300
| Phone | 41-41-561-32-77 | Revenue | 3.51M | |
| Industry | Biotechnology | Net Income | -581,599,000.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CRSP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1,343.497 |
| Price to Book Ratio | 2.617 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.355 |
| Enterprise Value to Sales | 837.311 |
| Total Debt to Enterprise Value | 0.07 |
CRSP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.002 |
CRSP Liquidity
| Current Ratio | 13.316 |
| Quick Ratio | 13.316 |
| Cash Ratio | 13.301 |
CRSP Profitability
| Gross Margin | -6,537.009 |
| Operating Margin | -16,191.396 |
| Pretax Margin | -16,466.239 |
| Net Margin | -16,569.772 |
| Return on Assets | -25.807 |
| Return on Equity | -30.182 |
| Return on Total Capital | -27.324 |
| Return on Invested Capital | -27.379 |
CRSP Capital Structure
| Total Debt to Total Equity | 10.758 |
| Total Debt to Total Capital | 9.713 |
| Total Debt to Total Assets | 9.127 |
| Long-Term Debt to Equity | 9.791 |
| Long-Term Debt to Total Capital | 8.84 |